Monoclonal antibody therapeutics: history and future

Kohler, 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, 495, 10.1038/256495a0 Ober, 2001, Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies, Int Immunol, 13, 1551, 10.1093/intimm/13.12.1551 Stern, 2005, Overview of monoclonal antibodies in cancer therapy: present and promise, Crit Rev Oncol Hematol, 54, 11, 10.1016/j.critrevonc.2004.10.011 Morrison, 1984, Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc Natl Acad Sci USA, 81, 6851, 10.1073/pnas.81.21.6851 Presta, 2006, Engineering of therapeutic antibodies to minimize immunogenicity and optimize function, Adv Drug Deliv Rev, 58, 640, 10.1016/j.addr.2006.01.026 Jones, 1986, Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, 321, 522, 10.1038/321522a0 McCafferty, 1990, Phage antibodies: filamentous phage displaying antibody variable domains, Nature, 348, 552, 10.1038/348552a0 Winter, 1994, Making antibodies by phage display technology, Annu Rev Immunol, 12, 433, 10.1146/annurev.iy.12.040194.002245 Vaughan, 1996, Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library, Nat Biotechnol, 14, 309, 10.1038/nbt0396-309 Vaughan, 1998, Human antibodies by design, Nat Biotechnol, 16, 535, 10.1038/nbt0698-535 Hoet, 2005, Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity, Nat Biotechnol, 23, 344, 10.1038/nbt1067 Jostock, 2004, Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries, J Immunol Methods, 289, 65, 10.1016/j.jim.2004.03.014 Boulianne, 1984, Production of functional chimaeric mouse/human antibody, Nature, 312, 643, 10.1038/312643a0 Lonberg, 1994, Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature, 368, 856, 10.1038/368856a0 Green, 1994, Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nat Genet, 7, 13, 10.1038/ng0594-13 Baker, 2010, Immunogenicity of protein therapeutics: the key causes, consequences and challenges, Self Nonself, 1, 314, 10.4161/self.1.4.13904 De Groot, 2008, Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates, Curr Opin Pharmacol, 8, 620, 10.1016/j.coph.2008.08.002 Lonberg, 2008, Fully human antibodies from transgenic mouse and phage display platforms, Curr Opin Immunol, 20, 450, 10.1016/j.coi.2008.06.004 Nelson, 2010, Development trends for human monoclonal antibody therapeutics, Nat Rev Drug Discov, 9, 767, 10.1038/nrd3229 Natsume, 2008, Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities, Cancer Res, 68, 3863, 10.1158/0008-5472.CAN-07-6297 An, 2009, IgG2m4, an engineered antibody isotype with reduced Fc function, MAbs, 1, 572, 10.4161/mabs.1.6.10185 Abès, 2010, Impact of glycosylation on effector functions of therapeutic IgG, Pharmaceuticals, 3, 146, 10.3390/ph3010146 Strohl, 2009, Optimization of Fc-mediated effector functions of monoclonal antibodies, Curr Opin Biotechnol, 20, 685, 10.1016/j.copbio.2009.10.011 Chan, 2010, Therapeutic antibodies for autoimmunity and inflammation, Nat Rev Immunol, 10, 301, 10.1038/nri2761 Hinton, 2004, Engineered human IgG antibodies with longer serum half-lives in primates, J Biol Chem, 279, 6213, 10.1074/jbc.C300470200 Hinton, 2006, An engineered human IgG1 antibody with longer serum half-life, J Immunol, 176, 346, 10.4049/jimmunol.176.1.346 Dall’Acqua, 2006, Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn), J Biol Chem, 281, 23514, 10.1074/jbc.M604292200 Salfeld, 2007, Isotype selection in antibody engineering, Nat Biotechnol, 25, 1369, 10.1038/nbt1207-1369 Stapleton, 2011, Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential, Nat Commun, 2, 599, 10.1038/ncomms1608 Aalberse, 2002, IgG4 breaking the rules, Immunology, 105, 9, 10.1046/j.0019-2805.2001.01341.x Labrijn, 2009, Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo, Nat Biotechnol, 27, 767, 10.1038/nbt.1553 Bloom, 1997, Intrachain disulfide bond in the core hinge region of human IgG4, Protein Sci, 6, 407, 10.1002/pro.5560060217 Lu, 2008, The effect of a point mutation on the stability of IgG4 as monitored by analytical ultracentrifugation, J Pharm Sci, 97, 960, 10.1002/jps.21016 Webb, 2011, Pharma interest surges in antibody drug conjugates, Nat Biotechnol, 29, 297, 10.1038/nbt0411-297 DeFrancesco, 2011, Seattle genetics rare cancer drug sails through accelerated approval, Nat Biotechnol, 29, 851, 10.1038/nbt1011-851 Junttila, 2011, Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer, Breast Cancer Res Treat, 128, 347, 10.1007/s10549-010-1090-x Hamann, 2002, Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody–calicheamicin conjugate for treatment of acute myeloid leukemia, Bioconjug Chem, 13, 47, 10.1021/bc010021y Sanderson, 2005, In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate, Clin Cancer Res, 11, 843, 10.1158/1078-0432.843.11.2 Alley, 2008, Contribution of linker stability to the activities of anticancer immunoconjugates, Bioconjug Chem, 19, 759, 10.1021/bc7004329 Shen, 2012, Conjugation site modulates the in vivo stability and therapeutic activity of antibody–drug conjugates, Nat Biotechnol, 30, 184, 10.1038/nbt.2108 Zhao, 2011, Synthesis and evaluation of hydrophilic linkers for antibody–maytansinoid conjugates, J Med Chem, 54, 3606, 10.1021/jm2002958 Pedersen, 2010, Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy, Cancer Res, 70, 588, 10.1158/0008-5472.CAN-09-1417 Mabry, 2010, Therapeutic bispecific antibodies: the selection of stable single-chain fragments to overcome engineering obstacles, IDrugs, 13, 543 Müller, 2010, Bispecific antibodies for cancer immunotherapy current perspectives, BioDrugs, 24, 89, 10.2165/11530960-000000000-00000 Linke, 2010, Catumaxomab: clinical development and future directions, MAbs, 2, 129, 10.4161/mabs.2.2.11221 Staerz, 1985, Hybrid antibodies can target sites for attack by T cells, Nature, 314, 628, 10.1038/314628a0 Baeuerle, 2009, BiTE: teaching antibodies to eng age T-cells for cancer therapy, Curr Opin Mol Ther, 11, 22 Banks, 2002, Passage of amyloid beta protein antibody across the blood–brain barrier in a mouse model of Alzheimer's disease, Peptides, 23, 2223, 10.1016/S0196-9781(02)00261-9 Pestalozzi, 2000, Trastuzumab in CSF, J Clin Oncol, 18, 2349, 10.1200/JCO.2000.18.11.2349 Stemmler, 2007, Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier, Anticancer Drugs, 18, 23, 10.1097/01.cad.0000236313.50833.ee Frank, 2011, Strategies for enhancing antibody delivery to the brain, Biochim Biophys Acta, 1816, 191 Patel, 2009, Getting into the brain: approaches to enhance brain drug delivery, CNS Drugs, 23, 35, 10.2165/0023210-200923010-00003 Silva, 2008, Nanotechnology approaches to crossing the blood–brain barrier and drug delivery to the CNS, BMC Neurosci, 10, S4, 10.1186/1471-2202-9-S3-S4 Yu, 2011, Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target, Sci Transl Med, 3, 84ra44, 10.1126/scitranslmed.3002230 Boado, 2010, IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey, Biotechnol Bioeng, 105, 627, 10.1002/bit.22576 Abulrob, 2005, The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells, J Neurochem, 95, 1201, 10.1111/j.1471-4159.2005.03463.x Rutgers, 2011, Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood–brain barrier, Neuroscience, 190, 37, 10.1016/j.neuroscience.2011.05.076 Brambell, 1964, A theoretical model of gamma-globulin catabolism, Nature, 203, 1352, 10.1038/2031352a0